Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -13.60 -0.82% 1,637.60 1,633.40 1,634.00 1,651.00 1,628.00 1,642.20 8,408,577 16:35:23
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 33,754.0 6,221.0 93.9 17.4 82,159

Glaxosmithkline Share Discussion Threads

Showing 18951 to 18973 of 21450 messages
Chat Pages: Latest  762  761  760  759  758  757  756  755  754  753  752  751  Older
DateSubjectAuthorDiscuss
24/1/2019
07:49
Totally irrelevant, considering I hold GSK.
gbh2
23/1/2019
20:05
much better than aim stock
billionairepaddy
23/1/2019
19:57
Dire share price performance atm !
gbh2
23/1/2019
10:54
GlaxoSmithKline has a share of around 5% of the world's pharmaceutical market. The company employs around 99,300 people in over 100 countries. In 2010 they delivered 1.4 billion vaccine doses to 179 countries. As of today, it has a market capitalisation of £73.5 billion, the seventh largest on the London Stock Exchange. I'm staying put ….. at least till Emma's plan materialises ;0) P.S. I buy large quantities and sell on the swings to regularly gain small increments. That, plus the dividends covers my needs - and I always re-invest the returns.
tradermichael
23/1/2019
09:49
When everything digested these will be higher, seems a crazy price.
montyhedge
23/1/2019
09:44
GSK completes acquisition of TESARO, an oncology focused biopharmaceutical company GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has successfully completed the acquisition of TESARO, Inc. an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (GBP4.0 billion). The transaction, which was announced on 3 December 2018, significantly strengthens GSK's pharmaceutical business, accelerating the build of GSK's pipeline and commercial capability in oncology. That's not good news TM! They already had crippling debt levels and this big transaction, being for cash, must worsen that. It was known for some time but the news of completion is nothing to celebrate, quite the reverse. :~( What an appalling share GSK has been for long term growth investors. Glad I'm not one :~)
anhar
23/1/2019
09:02
£1 = US$1.30
tradermichael
22/1/2019
17:44
Nice and steady 👍
philanderer
22/1/2019
16:13
GSK completes acquisition of TESARO, an oncology focused biopharmaceutical company GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has successfully completed the acquisition of TESARO, Inc. an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (GBP4.0 billion). The transaction, which was announced on 3 December 2018, significantly strengthens GSK's pharmaceutical business, accelerating the build of GSK's pipeline and commercial capability in oncology.
tradermichael
22/1/2019
13:05
Thanks all
watfordhornet
22/1/2019
12:57
Announcement date, Wednesday 6 February 2019. Ex-dividend date*, Thursday 21 February 2019. Record date, Friday 22 February 2019 Apparently.
wbecki
22/1/2019
12:57
2018 Q4 Ex-dividend date Thursday 21 February 2019 hTTps://www.gsk.com/en-gb/investors/shareholder-information/dividend-calendar/
tradermichael
22/1/2019
12:55
When does this go ex divi for next qtr payment. Apologies if obvious but cannot find the date
watfordhornet
22/1/2019
12:21
Can't get pass 1500p 1499p was the best so far.
montyhedge
22/1/2019
10:16
SP is very unstable.
abdullla
22/1/2019
08:55
1500p resistance point, but if break through and hold at close, that's a great pivotal point broken. Then onwards and upwards.
montyhedge
21/1/2019
15:29
RALLYYYYYYYYYY on this undiscovered stock .... Futura Medical (FUM)= Market cap 20 million /Cash 10.5 million / Potency Drug with 2 BILLION Market potential close to Phase 3 readout /CSD500 Condom approved in Europe and many Countries outside of Europa + more Approvals & Licensing deals coming / TPR100 (Topical Gel for Pain ) first approval expected next Quarter = POTENTIAL 10++ BAGGER GEM Futura Medical featured in Growth Company Investor recommendations 08 January 2019 CEO James Barder describes Futura as a medtech rather than biotech business. Its proprietary technology is DermaSys which delivers drugs rapidly through the skin and into the blood system. The lead product is MED2005 which is a topical gel for erectile dysfunction. The main advantage over Viagra is that it takes effect within five minutes, compared with over an hour for the famous blue pills. Which ensures key ingredients of spontaneity and mood can be retained while the treatment works. Research suggests a 20% market share could be possible, equating to sales of $560m in major western markets. In time an OTC version could more than double this.
bioking
21/1/2019
15:14
I agree with TM, but Porsche is correct in saying that this share price is very disappointing. We talk about £16 or more but it is proving very difficult to stay above £15 just now. I believe EW has a fresh outlook, which is exciting and adventurous, but as yet with no evidence to give us real confidence. But I am sticking with GSK for now.
jadeticl3
21/1/2019
15:06
Not forgetting the value to be unlocked by Consumer Healthcare
tradermichael
21/1/2019
15:03
I'm happy with it. Risk is limited and potential upside is good (e.g. Shingrix, immuno-oncology). The dividend will increase with the turnaround as well. Has global market, protected by US $ earnings.
tradermichael
21/1/2019
14:37
what a dissapointing share to own this is, zero capital growth, people bang on about yield but you can pick up 30 pc higher yields from some income funds without the stock specific risk....Asta Z really shown these up.
porsche1945
21/1/2019
11:51
Quiet day today , US markets closed for Martin Luther King holiday.
philanderer
21/1/2019
11:03
Analyst on CNBC said pharma's place to be, thats good, I'm already there, lol. Should have a run after the figures. 23p dividend in the bag coming.
montyhedge
Chat Pages: Latest  762  761  760  759  758  757  756  755  754  753  752  751  Older
ADVFN Advertorial
Your Recent History
LSE
GSK
Glaxosmith..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200606 20:52:14